

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of contents of this announcement.*

*This announcement appears for information only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of Sinopharm Tech Holdings Limited nor anything herein forms the basis for any contract or commitment whatsoever.*



**Sinopharm Tech Holdings Limited**

**國藥科技股份有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8156)**

## **LAPSE OF THE ISSUE OF CONVERTIBLE BONDS UNDER THE SECOND SUBSCRIPTION AGREEMENT**

References are made to the announcements of the Sinopharm Tech Holdings Limited (the “**Company**”) dated 20 August 2021 (the “**Announcement**”) and 23 August 2021 in relation to issuance of the convertible bonds of an aggregate principal amount of HK\$100,000,000. Terms used herein shall have the same meanings as those defined in the Announcement unless otherwise specified.

In addition to the completion of the subscription of the convertible bonds of the principal amount of HK\$50,000,000 contemplated under the First Subscription Agreement on 30 August 2021 as disclosed in the announcement of the Company on the same date, the Company would like to provide the Shareholders and potential investors of the Company with an update of the subscription of the convertible bonds of the principal amount of HK\$50,000,000 (the “**Second Convertible Bonds**”) contemplated under the Second Subscription Agreement. As the conditions precedent set out in the Second Subscription Agreement have not been fully fulfilled (or as the case may be, waived) on or before the Second Long Stop Date on 19 October 2021, the subscription of the Second Convertible Bonds contemplated under the Second Subscription Agreement have lapsed, determined and been of no further effect. No party shall be liable to the other save and except antecedent breach committed before the termination of the Second Subscription Agreement.

The Board is of the view that the lapse of the subscription of the Second Convertible Bonds contemplated under the Second Subscription Agreement will not have any material adverse effect on the financial position and business operations of the Group.

By Order of the Board  
**Sinopharm Tech Holdings Limited**  
國藥科技股份有限公司  
**CHAN Ting**  
Chairperson

Hong Kong, 19 October 2021

*As at the date of this announcement, the Board comprises Mr. CHAN Ting, Mr. LIAO Zhe and Mr. CHEUK Ka Chun Kevin as executive Directors, Madam CHEUNG Kwai Lan and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for a minimum period of 7 days from the date of its publication and on the website of the Company at [www.sinopharmtech.com.hk](http://www.sinopharmtech.com.hk).*